司美格鲁肽大消息!诺和诺德首次官宣

健识局
22 Apr

4月21日,诺和诺德与京东健康达成战略合作,将进一步加深在糖尿病和体重管理领域的共建。健识局获悉,双方将携手打造肥胖症公众科普专区,助力糖尿病一站式诊疗,全面赋能慢病管理数字化转型升级。同时,诺和诺德还首次将“诺和泰”、“诺和忻”等多款不同适应症、不同剂型的司美格鲁肽正式搬到电商平台销售,开创中国GLP-1药物销售格局的先河。诺和诺德全球高级副总裁兼大中国区总裁周霞萍女士表示:在健康中国战略纵深...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10